Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Alcobra Reports Adult ADHD Drug Failed Late-Stage Study

By Ryan Bushey | January 18, 2017

Alcobra, a pharmaceutical company based in Israel, announced on Tuesday that its experimental drug for treating attention deficit hyperactivity disorder (ADHD) missed its primary endpoint in a second Phase 3 clinical trial.

The drug is called Metadoxine Extended Release (MDX), which was being tested as therapy for adults with ADHD in a study featuring 283 patients.

Results from the trial had failed to produce a statistically significant benefit from placebo in helping patients cope with the symptoms forcing the company to end the ADHD development program.

“We are exceedingly disappointed with these top-line results. In the coming weeks, the company intends to review the full data set from MEASURE. Consequently, we will evaluate our options and communicate our strategic plan to investors,” said Alcobra’s President & CEO Yaron Daniely, Ph.D., in a statement.

MDX has traversed a difficult path during the research and development process.

The Food and Drug Administration placed a full clinical hold on the drug in September 2016 after reviewing preclinical data that indicated “adverse neurological findings,” showing potentially damaging effects on peripheral nerve function in animal studies,according to FierceBiotech.

The full clinical hold became partial last month, but the primary concern with this therapy was the efficacy of it instead of safety concerns during human trials. MDX was well tolerated in this recent evaluation as well.

Essentially, the hope was that MDX could give Alcobra an advantage in the growing ADHD treatment market. A report from research and consulting firm GlobalData predicts this market could be a lucrative opportunity for drugmakers who create new effective treatment options.

Alcobra may continue developing MDX for other treatment options such as Fragile X syndrome, which is a rare genetic condition that can cause intellectual disability.

The company’s share price is currently down almost 50 percent in mid-day trading.


Filed Under: Drug Discovery

 

Related Articles Read More >

If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
Antibody - visual concept of immune System - 3D illustration
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
Physician in a white coat reviewing information on a tablet with a patient in an exam room.
What real-world data shows about current cancer care
Roche Towers, Basel, Switzerland
Roche picks cancer targets, Hansoh builds the ADCs in deal with $400 million upfront
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE